First Trimester Biochemical Screening for Trisomy 21: The Role of Free Beta hCG, Alpha Fetoprotein and Pregnancy Associated Plasma Protein A
- K. Spencer, D. Aitken, J. Macri
- Medicine, BiologyAnnals of Clinical Biochemistry
- 1 September 1994
First trimester screening using free β human chorionic gonadotropin and α fetoprotein, is a viable possibility and will lead to detection rates in excess of 50%.
Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free beta-hCG subunit.
- K. Spencer, J. Macri, P. Carpenter, R. Anderson, D. Krantz
- BiologyClinical Chemistry
- 1 June 1993
It is found that, in practice, any changes in free beta-hCG due to the instability of intact hCG do not inhibit the effectiveness of free Beta-h CG as a marker for Down syndrome.
A prognosis-based approach to infertility: understanding the role of time
- D. Albertini, R. Anderson, A. V. van Steirteghem
- MedicineHuman Reproduction
- 1 August 2017
An alternative and innovative vision of infertility based on prognosis may be a valid solution and the availability of validated dynamic models based on real-life data that could predict both natural and ART-mediated conceptions may be of benefit.
Dual Analyte Immunoassay in Neural Tube Defect and Down's Syndrome Screening: Results of a Multicentre Clinical Trial
- K. Spencer, J. Macri, R. Wilmot
- Medicine, BiologyAnnals of Clinical Biochemistry
- 1 July 1993
It is concluded that the combination of clinically superior markers coupled with technologically innovative assay design will lead to more efficient Down's screening programmes.
Dual Analyte Immunoassay—a New Approach to Neural Tube Defect and Down's Syndrome Screening
- J. Macri, K. Spencer, R. Anderson
- Biology, MedicineAnnals of Clinical Biochemistry
- 1 July 1992
The Dual Analyte approach, which combines analytes achieving the highest known detection efficiency, will bring about improvements in the efficiency of screening, reduce costs and improve report turnaround, all leading to better quality of patient care.
Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome.
- J. Macri, R. Anderson, D. Krantz, J. Larsen, P. Buchanan
- MedicineAmerican Journal of Obstetrics and Gynecology
- 1996
Second-trimester dried blood screening for open neural tube defects and Down syndrome can achieve screening efficiency comparable to serum-based protocols with distinct advantages over the conventional method of blood collection.
Alpha-fetoprotein in diabetic pregnancy. A reassessment.
- T. Tharakan, L. Baxi, D. Kramer, R. Anderson
- MedicineJournal of reproductive medicine
- 1 December 1993
No significant decrease in MSAFP was seen in pregestational diabetics, and no correlation was seen with HbA1 levels, and AFAFP levels were unchanged in diabetic patients.
Evaluation of an automated enzyme-linked fluorescent assay for thyroxine measurement in cat and dog sera
- R. Anderson, R. Mueller, S. Reese, A. Wehner
- Biology, MedicineJournal of Veterinary Diagnostic Investigation
- 29 March 2017
Both methods yielded acceptable results, but the EIA was more accurate compared to the ELFA (percentage of true-positives in cats and dogs: EIA: 97% and 100%; ELFA: 92% and 94%).
Free beta-chorionic gonadotropin: a cross-reactivity study of two immunometric assays used in prenatal maternal serum screening for Down's syndrome.
- J. Macri, K. Spencer, R. Anderson, E. J. Cook
- Biology, MedicineAnnals of Clinical Biochemistry
- 1993
It is concluded that properly designed free beta assays will provide specific analyte measurement and improved detection efficiency in Down's syndrome screening.